A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia.

Objective: To examine the hypnotic efficacy of zaleplon 10 mg, a selective benzodiazepine receptor agonist, over a period of 35 nights in primary insomniacs.Methods: A double-blind, parallel-group, placebo-controlled design was employed. Subjects were 113 men and women, ages 18 to 65 years. Polysomnographic and subjective sleep data were collected during baseline, on two nights during each of five treatment weeks, and on the first two nights after discontinuation of active medication.Results: Sleep latency was significantly shortened with zaleplon 10 mg for all 5 weeks of treatment as assessed by polysomnography and by subjective sleep measures. Total sleep time, whether evaluated with polysomnography or with subjective estimates, was inconsistently affected. Sleep architecture was similar with zaleplon and placebo. There was no evidence of tolerance to the sleep promoting effects of zaleplon during the five weeks of administration, and there was no rebound insomnia upon discontinuation. Adverse events occurred with equal frequency in the zaleplon and placebo groups.Conclusions: Zaleplon 10 mg is effective in the treatment of sleep onset insomnia over a period of 35 nights, with minimal evidence of undesired effects.

[1]  A. Rechtschaffen,et al.  A manual of standardized terminology, technique and scoring system for sleep stages of human subjects , 1968 .

[2]  V. Shu,et al.  Efficacy of estazolam. The United States clinical experience. , 1990, The American journal of medicine.

[3]  J. Hedner,et al.  Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia , 2000, International journal of geriatric psychiatry.

[4]  J. Coquelin,et al.  Long-Term Polysomnographic Study of the Efficacy and Safety of Zolpidem in Elderly Psychiatric In-Patients with Insomnia , 1993, The Journal of international medical research.

[5]  S. Ancoli-Israel,et al.  Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects. , 1999, Primary care companion to the Journal of clinical psychiatry.

[6]  D. Greenblatt,et al.  Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo , 1998, Clinical pharmacology and therapeutics.

[7]  I. Oswald,et al.  Benzodiazepine hypnotics remain effective for 24 weeks. , 1982, British medical journal.

[8]  M. Leibowitz,et al.  Long‐Term Hypnotic Efficacy and Safety of Triazolam and Flurazepam , 1978, Journal of clinical pharmacology.

[9]  D. Monti,et al.  Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients. , 1994, Pharmacopsychiatry.

[10]  J. Barrett,et al.  A Review of the Preclinical Development of Zaleplon, a Novel Non-Benzodiazepine Hypnotic for the Treatment of Insomnia , 1997 .

[11]  N. Nandwani,et al.  Obstructive sleep apnoea and upper airway reactivity , 1998, Journal of sleep research.

[12]  T. Roth,et al.  Issues in the use of benzodiazepine therapy. , 1992, The Journal of clinical psychiatry.

[13]  C. Pollak,et al.  Lack of Residual Sedation Following Middle-of-the-Night Zaleplon Administration in Sleep Maintenance Insomnia , 2000, Clinical neuropharmacology.

[14]  E. Bixler,et al.  Early morning insomnia with rapidly eliminated benzodiazepines. , 1983, Science.

[15]  J K Walsh,et al.  A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. , 1994, The Journal of clinical psychiatry.

[16]  T. Roth,et al.  Efficacy and Tolerability of 14-Day Administration of Zaleplon 5mg and 10mg for the Treatment of Primary Insomnia , 1998 .

[17]  H. Meltzer,et al.  Psychopharmacology : the third generation of progress , 1987 .

[18]  W. Cevallos,et al.  A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. , 2001, British journal of clinical pharmacology.